Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Quote from Bloomberg
"DnaNudge said it will provide 5.8 million tests along with processing equipment in a deal worth about 161 million pounds ($211 million). The technology allows doctors and nurses to quickly determine whether patients are infected in emergency settings and before undergoing surgery, cancer care and other procedures, the company said."
https://www.bioworld.com/articles/496306-codagenix-plans-a-human-challenge-trial-to-test-its-covid-19-vaccine
But Challenge Studies must be by far the faster route …. and that’s what the world urgently needs right now!
Note the quote from EMA on challenge trials:
“The European Medicine Agency (EMA) said challenge trials would be useful in various parts of the vaccine development process, in particular in gauging correlates of protection and providing useful information to speed regulatory decisions.”
Lets hope so eh!
...... and some folks are selling!!! Unbelievable but typical short sighted investors! Emailed Cathel and suggested he lists OO on nasdaq ASAP.
Will be interesting to see if todays news attracts USA investors to buy shares.
Imutex mentioned as a key player in this Flue Vaccine Article. It must be worth a bomb and rubbing shoulders with the big boys!
https://www.medgadget.com/2020/07/influenza-vaccine-market-global-analysis-growth-trend-share-size-opportunity-and-forecast-till-2026.html
I see Catenae’ Covid 19 Passport can also be adopted to be a Digital Health Wallet for recording a persons vaccination records.
Verifications including:
COVID-19, Ebola, Malaria, Yellow Fever etc.
Chronic and non-communicable disease records
Infectious disease records
This what Afrik-ID are currently trialling for 4 months in Botswana along with Catenae’s 'Onsite ID', a new multi-document digital wallet.
A system that allows potential employers to access IDs and qualifications to avoid fraud, that can often happen with paper-based processes.
Agree AquaeSulis01! Thats the skills the CHIMagents bring to Open Orphan. Plus Open Orphen employ specialist virologists that could also help modify the COVID-19 virus. This could be the exciting news that Adrian recently indicated is coming.
Directors future rewards all sorted I see!
Set for launch now me thinks!
GLA
Puzzled to how Oxford Uni thinks they can have their vaccine available soon! Stage 3 without a challenge study will take much longer to achieve. Surely they are not thinking of doing their own challenge study without the full set up OO have. Someone needs to point them in OO's direction and let UK gov know too that they have a top class world leading company that can do the job for them. I will be gob smacked if UK does not use OO and lets other countries pharms beat them in the race for a vaccine. Still on current COVID performance our Uk gov I am left wondering & somewhat puzzled why OO services are not being snapped up......... or are they?!
Whoops I stand corrected!!!
IFN-B is good for all covid patients, not just the seriously ill. The company's belief is that the earlier in the infection cycle it's given, the better the outcome, although I note they seem to have stepped back a little from that in the latest RNS.
It doesn't need a challenge study - it's got conventional double-blind placebo-controlled results already. What I'm suggesting is that OO can now do covid vaccine challenge studies more safely because there's another effective treatment for people who succumb to the virus despite the vaccine ie it treats vaccine failures. As such it makes challenge studies more likely to be approved, which has got to be good for OO.
Syn's treatment 'breakthrough' is for patients in critical care - seriously ill and therefore in my opinion is not really applicable for protective agent use in a challenge study.
Lol !
Yes I am hoping to be called Quidsworth one day soon!
Just sneaked in with a 50,000 top up. Great Weekend All.
Can see why they are called CHIMagents.
"Controlled Human Infection Model (CHIM) studies, trials
that purposely infect human volunteers with infectious
agents (known as challenge agents), are an essential
component of pathology, immunology and vaccines
research. There are unique ethical, safety and scientific
challenges associated with CHIM studies that mean that
robust governance and appropriate regulation is
essential to their effective use and continued growth."
Taken from ADVFN BB - Brasso3
Http://chimagents.com/
CHIMagents is a company of experienced and committed individuals building a portfolio of challenge agents to be used in controlled human infection studies.
Controlled human infection studies are becoming more-and-more important for pharmaceutical companies to take Go/No-Go decisions in the development track of potential vaccines and anti-viral drugs.
Together with Key Opinion Leaders and Subject Matter Experts in the field, CHIMagents identify relevant strains and guide development and manufacturing of new challenge agents according to (c)GMP to ensure they are authorised for use in clinical trials in the EU and US.
CHIMagents – experts in Controlled Human Infection Models.
1st Country to do so & will not be the last!
Bit basic but its a start of things to come!
https://www.independent.co.uk/news/world/europe/denmark-coronavirus-passport-travel-covid-19-a9609801.html